Like targets at a Department of Justice shooting gallery, drugmakers are going down on marketing violations. The latest is Forest Laboratories, which agreed to a $313 million settlement. The misbehavior: selling an unapproved drug, marketing another drug off-label, and lying to FDA inspectors during a visit. The company's Forest Pharmaceuticals unit pleaded guilty to criminal charges of marketing...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Forest Labs inks $313M settlement with DoJ
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account